Anticoagulant treatment as a risk factor for primary intracerebral haemorrhage

R Fogelholm, K Eskola, T Kiminkinen, I Kunnamo

Abstract
Forty one (14.2%) of 288 patients with primary intracerebral haemorrhage occurring between September 1985 and December 1989 in Central Finland were on anticoagulant treatment at the onset of symptoms. In a sample of 29 000 subjects from the same population the prevalence of anticoagulant treatment was 1.6% in those aged 40 years or older. The estimated age adjusted odds ratio of being on anticoagulant treatment at the time of primary intracerebral haemorrhage was 6.7 (95% CI from 4.5 to 9.9). The risk was highest during the first year of anticoagulation. Over-treatment (thrombostest value < 5%) was slightly more common among the patients. The haematoma volumes measured from the CT scans were similar in patients on anticoagulant treatment and those not anticoagulated. The case fatality rate during the first week and the mortality during follow up of 32 months were slightly higher, and the functional outcome slightly worse in the anticoagulated group.

(J Neurol Neurosurg Psychiatry 1992;55:1121–1124)

Bleeding complications are inherent risks of anticoagulant (AC) treatment and most of the fatal bleedings are intracranial. In studies on spontaneous intracerebral haemorrhage during the era of CT the prevalence of patients being on AC treatment at the onset of bleeding has varied from 9%–23.2-8 The factors in which the magnitude of the risk of intracerebral haemorrhage during AC treatment has been estimated as 7–6–11 times higher than that of patients not on AC treatment. In addition, factors possibly contributing to this increased risk have been identified, for example, the level of anticoagulation, the duration of the AC treatment, and hypertension.

The aim of this retrospective study was to estimate the magnitude of the increased risk of primary intracerebral haemorrhage (PICH) during AC treatment, and to find out factors possibly associated with this risk. The study was based on a representative patient material with either CT or necropsy confirmation of the diagnosis, and on prevalence data of AC treatment in a sample of the same population from which the patients emerged. In addition, we compared the haematoma volumes and the outcome of patients on AC treatment with those not anticoagulated.

Patients and methods
During the period from 1 September 1985 to 31 December 1989 a total of 293 patients with PICH were diagnosed in a population of 245 000 in Central Finland (fig 1). The diagnosis was confirmed in 237 cases by CT, and in 56 cases by necropsy. Of these patients 158 have been included in an epidemiological study on the population of 116 000 living in the Jyväskylä Region,8 the other 135 patients are from other parts of Central Finland. The patients in this study were traced from: a) files of the Department of Neurology; b) discharge lists of the Central Hospital, the Health Centres, and the Department of Neurosurgery, University of Kuopio; c) lists of death certificates of Central Finland, and d) medical and medico-legal necropsy reports. The diagnosis of PICH excludes haemorrhages due to trauma, rupture of an arterial aneurysm or arterio-venous malformation, or bleeding from cerebral neoplasm.

On the basis of the figures from the epidemiological study from the Jyväskylä Region8 we estimated that 90% of all PICH cases aged less than 69 years, 71% aged 70–79 years, and 50% aged 80 years or more that occurred in Central Finland during the study period were included in our analysis. Data on AC treatment, previous hypertension, stroke, and cardiac diseases was obtained in 288 patients which form the basis of this study.

The CT examinations were performed within 24 hours of onset in 43%, and within 72 hours in 90% of the patients. The location of the haematomas on the CT films was assessed applying the anatomical atlas of Kretschmann and Weinrich.11 The haematoma volumes were measured from the CT films using a computer program. The area of the haemorrhage in each slice was measured planimetrically and multiplied by the thickness of the slice. The sum of these subvolumes gave the total haematoma volume.

At the end of follow up (31 August 1990) all patients who had been discharged alive were contacted by telephone, or in the case of death or severe handicap a relative or carer was interviewed. The functional outcome was assessed using the Rankin grading system12 and the cause of death obtained from the death certificates was confirmed by data from the medical and necropsy records.
Table 1 Prevalence of anticoagulant treatment among patients with primary intracerebral haemorrhage in Central Finland 1985–89

<table>
<thead>
<tr>
<th>Age</th>
<th>Men</th>
<th>Women</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AC+ (%)</td>
<td>AC+ (%)</td>
<td>AC+ (%)</td>
</tr>
<tr>
<td>30–39</td>
<td>3 (33)</td>
<td>4 (25)</td>
<td>7 (24)</td>
</tr>
<tr>
<td>40–49</td>
<td>13 (15)</td>
<td>4 (25)</td>
<td>17 (25)</td>
</tr>
<tr>
<td>50–59</td>
<td>26 (14)</td>
<td>14 (17)</td>
<td>40 (16)</td>
</tr>
<tr>
<td>60–69</td>
<td>49 (6)</td>
<td>46 (8)</td>
<td>95 (14)</td>
</tr>
<tr>
<td>70–79</td>
<td>44 (9)</td>
<td>57 (10)</td>
<td>101 (19)</td>
</tr>
<tr>
<td>Total</td>
<td>139 (18)</td>
<td>149 (23)</td>
<td>288 (41)</td>
</tr>
</tbody>
</table>

AC+ = patients on anticoagulation.

Table 2 Prevalence of anticoagulant treatment in 1989–90 in a population sample from Central Finland, aged 40 years or over

<table>
<thead>
<tr>
<th>Age</th>
<th>Men</th>
<th>Women</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AC+ (%)</td>
<td>AC+ (%)</td>
<td>AC+ (%)</td>
</tr>
<tr>
<td>40–49</td>
<td>1912 (5)</td>
<td>1825 (2)</td>
<td>3737 (7)</td>
</tr>
<tr>
<td>50–59</td>
<td>1686 (23)</td>
<td>1692 (8)</td>
<td>3378 (31)</td>
</tr>
<tr>
<td>60–69</td>
<td>1360 (34)</td>
<td>1799 (31)</td>
<td>3159 (65)</td>
</tr>
<tr>
<td>70–79</td>
<td>706 (31)</td>
<td>1728 (39)</td>
<td>2078 (70)</td>
</tr>
<tr>
<td>80+</td>
<td>231 (12)</td>
<td>573 (22)</td>
<td>804 (34)</td>
</tr>
<tr>
<td>Total</td>
<td>5985 (106)</td>
<td>7171 (102)</td>
<td>13156 (208)</td>
</tr>
</tbody>
</table>

No = number of persons.
AC+ = number of patients on anticoagulation.

Usually the long-term AC treatment is managed by the patient's primary care physician at the local Health Centre, and the intensity of treatment is controlled on average once a month. Thrombostest values between 5% and 15% (INR between 4.8 and 2.1) are considered effective. The Health Centres use the same thromboplastin reagent, and the comparability of the thrombostest values is controlled four times annually by the laboratory of the Central Hospital of Central Finland, Jyväskylä.

The prevalence of AC treatment in Central Finland was estimated by collecting data on all thrombotests performed during a six to eight week period in 1989–90 by the laboratories of the Health Centres of Keuruu, Karstula and Saarijärvi (fig 1) with a total population of 29,000 (12% of the population of Central Finland). The medical records of all patients with thrombotest during the observation period were examined, and those on AC treatment were included. In cases of PICH the thrombotest value was obtained at the onset of symptoms (or the most recent value before onset) and included in the analysis.

The confidence intervals (CI) of prevalence rates were calculated using the tables of Schoenberg, and of the medians according to Campbell and Gardner. The significance of a difference between proportions was calculated by the chi-square test. The Mantel-Haenszel method was applied in calculating the summary odds ratio (OR).

Results

Forty one (14.2%) of the 288 PICH patients were on AC treatment at the onset of symptoms, and all except one were over 40 years of age (table 1). The prevalence of AC treatment in the sample population aged 40 years or older was 1.6% (95% CI 1.4–1.9), and there was a steady increase in the prevalence figures by age (table 2). The odds ratio of PICH adjusted for age of persons on AC treatment was 6.7 (95% CI 4.5–9.9) compared with those not on AC treatment, 5.6 (95% CI 3.3–9.6) for men and 7.2 (95% CI 4.3–12.1) for women. There was no trend in the ORs by age the values varying between 2.8 and 8.2 in the age groups over 50 years.

Figure 1 Map of Central Finland. The Jyväskylä Region is hatched, and the Health Centres included in the population study are numbered: 1 = Keuruu, 2 = Saarijärvi, and 3 = Karstula.
The indications of AC treatment of the PICH patients and the population sample were similar (table 3).

The average duration of AC treatment of patients with PICH was shorter than in the population; 44% of the PICH patients had been on AC treatment for less than 1 year, half of these for less than 4 months, compared with 19% of the population sample (fig 2). Conversely, long-term treatment (> 5 years) was more common in the population sample. The trend was statistically highly significant ($x^2 = 19.0 \ df = 5 \ p = 0.002$).

The most recent thrombotest before onset of PICH was measured in 76% of patients within two weeks, most often on the day of onset. Overtreatment (thrombotest < 5%) was slightly more common among PICH patients (4/41) than among the population sample (6/208) ($x^2 = 4.2 \ p = 0.04$).

Lobar and posterior fossa haematomas were slightly more frequent in PICH patients on AC treatment but deep basal ganglionic haematomas were more common in patients not on AC treatment. Twenty seven (66%) of the AC treated, and 206 (83%) of the non-anticoagulated PICH patients had CT examination. The median haematoma volume was 24 ml (95% CI 11–49 ml) in patients on AC treatment, and 23 ml (95% CI 19–34 ml) in those not anticoagulated, the corresponding figures of patients dying within 7 days of onset were 62 ml (95% CI 16–140 ml) and 73 ml (95% CI 57–86 ml). The thrombotest values and the haematoma volumes did not correlate ($n = 27 \ r = 0.14 \ p = 0.5$).

Coronary heart disease, congestive heart failure, atrial fibrillation, and ischaemic cerebrovascular disease were statistically significantly more prevalent in patients on AC treatment (table 4), and was readily explained by selection due to the indications of anticoagulant treatment. The CT confirmed location of the previous ischaemic brain infarction was the same as the present haemorrhage in only 5/13 (38%) of the cases.

The case fatality rate during the first week after onset was 54% among the AC treated, and 40% among the non-anticoagulated, and after a median follow up of 32 months was 71% of the AC treated, and 61% of those non-anticoagulated. The differences were non-significant. The functional outcome at the end of follow up, assessed by the Rankin grading system was similar in both patient groups, half of the patients being independent (Ranking groups 1 and 2) in the ADL. Poor outcome (Ranking grade 5) was, however, more common among the AC treated than the non-anticoagulated (2/12 and 4/97), a statistically non-significant difference.

### Discussion

#### 1. Comparison with population data

The 288 PICH patients included in this study can be considered fairly representative of the disease as it occurs in the population, especially in those under the age of 80 years. A more difficult question is how well the chosen population sample from the three Health Centres represents the population of Central Finland. Because the distribution of the indications of anticoagulant treatment and the thrombotest values were quite similar in these Health Centres it is assumed that they are a fairly good representation of the whole of Central Finland, the catchment area of the Central Hospital. On the other hand, the age and sex adjusted prevalence rates of AC treatment for those aged 40 years or over varied between 1.14% and 1.88% in the chosen Health Centres, and this indicates the presence of possible differences in the use of anticoagulants.

The age adjusted OR 6.7 obtained in our study agrees with earlier reports.** Age had no impact on the ORs, as previously reported.*

The duration of the AC treatment was more often less than 1 year in PICH patients compared with the population sample. Similar accumulation of intracerebral haemorrhages in the first year of treatment has been observed in earlier studies.** In one of these studies, however, the mean duration of AC treatment

### Table 3: Indications for anticoagulant treatment in patients with primary intracerebral haemorrhage, and in the population sample

<table>
<thead>
<tr>
<th>Indicator</th>
<th>PICH (N = 41)</th>
<th>Population (N = 208)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No (%)</td>
<td>No (%)</td>
</tr>
<tr>
<td>Cardiac disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Atrial fibrillation</td>
<td>30 (73)</td>
<td>151 (73)</td>
</tr>
<tr>
<td>- MI/CHD</td>
<td>1 (2)</td>
<td>21 (10)</td>
</tr>
<tr>
<td>- Valvular disease</td>
<td>1 (2)</td>
<td>15 (7)</td>
</tr>
<tr>
<td>- Other</td>
<td>1 (2)</td>
<td>12 (6)</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>5 (12)</td>
<td>30 (14)</td>
</tr>
<tr>
<td>Deep vein thrombosis/pulmonary embolism</td>
<td>3 (7)</td>
<td>103 (50)</td>
</tr>
<tr>
<td>Ophthalmic artery/vein thrombosis</td>
<td>5 (12)</td>
<td>39 (19)</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>2 (5)</td>
<td>7 (3)</td>
</tr>
</tbody>
</table>

MI = myocardial infarction; CHD = coronary heart disease; PICH = primary intracerebral haemorrhage; POPULATION = population sample.

The totals exceed the number of patients because of two or more simultaneous indications of anticoagulation in some patients.

### Figure 2: Distribution of patients with primary intracerebral haemorrhage (PICH), and of the population sample from Central Finland, aged over 40 years, by duration of anticoagulant treatment.
before the haemorrhage was longer than that of all AC treated patients. In one prospective study\(^1\) with patients anticoagulated for various reasons, most of the major bleeding complications also occurred during the first month of treatment. Overtreatment has been associated with increased risk of intracerebral haemorrhage\(^1\),\(^2\) and also in our study overtreatment was three times as common among the PICH patients as in the population sample. Most of the patients were, however, within therapeutic range, in some,\(^7\)\(^9\) but not all\(^16\) earlier studies. The indications of AC treatment of the PICH patients were similar with the population sample. The true magnitude of the risk of PICH in patients anticoagulated for various indications can be estimated only by randomised controlled prospective studies.\(^7\) After strict exclusion criteria in non-valvular atrial fibrillation, PICH has been described as three times higher than in patients not anticoagulated.\(^16\) Our observations suggest that the risk is approximately sevenfold, and is especially high during the first year of treatment.

\section*{2 Comparison of anticoagulated with non-anticoagulated PICH patients}

The higher prevalence of cardio- and cerebrovascular diseases, except hypertension, among the AC treated patients can be explained solely by the indications of AC treatment. One point of interest is that the location of the previous ischaemic brain infarction, diagnosed by CT, was the same as the PICH in only one third of cases, a finding similar to a recent study.\(^7\) This finding does not support the theory of weakened vascular wall after ischaemia. The haematoma volumes measured from the CT films were similar regardless of anticoagulant status when all cases were included, as well as when the patients dying within the first week of onset, were analysed separately. This is in contrast to earlier studies of AC treated patients reported to have larger haematomas.\(^7\)\(^9\)\(^16\) The higher proportion of AC treated cases (34\%) compared with the non-anticoagulated cases (17\%) diagnosed at necropsy may distort the volume analysis. Large haematomas have a high early case fatality rate and thus may escape CT examination and volume measurement. Similar to an earlier study,\(^7\) the thrombotest values did not correlate with the haematoma volumes. In one other study, however, larger haematomas were associated with a more intense anticoagulation.

The trend of poorer short and long-term survival and functional outcome of the AC treated patients confirms the earlier observations.\(^7\)\(^9\) In one study the case fatality rate of the anticoagulated patients was even twice that of the non-anticoagulated.\(^7\)

To minimise the risk of PICH during AC treatment the indications for starting treatment should be stringent. Overtreatment should be avoided, and the duration of the treatment should be as short as possible.\(^9\) Low intensity anticoagulation might also significantly reduce the number of intracerebral haemorrhages,\(^20\) and in elderly patients all contraindications, concomitant diseases, and medications should be carefully considered.\(^21\)\(^22\) If the patient, however, suffers from a PICH, the outcome seems no worse than in patients without AC treatment.

We are grateful to Cees L. Franke, (Heerlen) and Jan-Ewoud Olson, (Linköping) for their valuable comments during the preparation of this manuscript.

\begin{table}
\centering
\begin{tabular}{|c|c|c|c|}
\hline
\textbf{Disease} & \textbf{AC+} & \textbf{AC-} \\
\hline
Hypertension & 22/41 (54) & 98/245 (40) \\
Coronary heart disease & 13/41 (32) & 33/245 (14)* \\
— myocardial infarction & 6/41 (15) & 10/245 (4)* \\
Congestive heart failure & 15/40 (38) & 40/245 (16) \\
Atrial fibrillation & 26/38 (68) & 23/245 (9)** \\
IBI & 13/40 (33) & 20/245 (8)** \\
\hline
\end{tabular}
\caption{Prevalence of cardiovascular disease, including ischaemic brain infarction in the case history of patients with primary intracerebral haemorrhage, by anticoagulant status}
\end{table}

\(^* p < 0.01; ** p < 0.001.
AC+ = on anticoagulation; AC- = not anticoagulated; IBI = ischaemic brain infarction.

---

Anticoagulant treatment as a risk factor for primary intracerebral haemorrhage.

R Fogelholm, K Eskola, T Kiminkinen and I Kunnamo

*J Neurol Neurosurg Psychiatry* 1992 55: 1121-1124
doi: 10.1136/jnnp.55.12.1121

Updated information and services can be found at:
http://jnnp.bmj.com/content/55/12/1121

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/